We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Senator Calls Mylan Response on EpiPen Pricing ‘Incomplete’
Senator Calls Mylan Response on EpiPen Pricing ‘Incomplete’
Sen. Chuck Grassley (R-Iowa) has deemed Mylan’s response to his inquiry on the cost of the company’s allergy drug EpiPen “incomplete,” asking for further detail on its price-setting analyses and the product features.